Responses
Regular and young investigator award abstracts
Clinical trials completed
303 Phase II trial of neoadjuvant nivolumab (Nivo) and intra-tumoral (IT) CMP-001 in high-risk resectable melanoma (Neo-C-Nivo): final results
Compose a Response to This Article
Other responses
No responses have been published for this article.
